Literature DB >> 8970715

HIV viral dynamics.

J M Coffin1.   

Abstract

BACKGROUND: Elucidation of the underlying rapid turnover of virus and HIV infected cells in vivo was perhaps the most informative and exciting discovery in HIV and AIDS research in the last few years. This observation, based on the rapid drop in virus load following antiviral drug therapy promises to change significantly the way we view important aspects of interaction of the virus and its host. As a result, the paradigm for HIV infection has shifted from considering the long period of clinical latency as one of viral inactivity, to viewing it as an active steady state of constant virus replication and cell death. This period should also be viewed as an integral part of the disease process, not simply a prolog to frank AIDS.
METHODS: Here, I discuss the theoretical basis of the steady state model of HIV infection as well as its important consequences for understanding and controlling HIV pathogenesis. These include the significance of genetic variation and the establishment and evolution of the virus quasispecies, the evolution of resistance of the virus to antiviral therapy, and the theoretical and practical significance of virus load measurements. Emphasis is on discussion of recent developments as well as areas where our understanding still has significant gaps.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8970715

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  22 in total

1.  Expression of CD28 and CD38 by CD8+ T lymphocytes in HIV-1 infection correlates with markers of disease severity and changes towards normalization under treatment. The Swiss HIV Cohort Study.

Authors:  P Bürgisser; C Hammann; D Kaufmann; M Battegay; O T Rutschmann
Journal:  Clin Exp Immunol       Date:  1999-03       Impact factor: 4.330

2.  An in vitro rapid-turnover assay for human immunodeficiency virus type 1 replication selects for cell-to-cell spread of virus.

Authors:  S Gummuluru; C M Kinsey; M Emerman
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

3.  Simian immunodeficiency virus envelope compartmentalizes in brain regions independent of neuropathology.

Authors:  Maria F Chen; Susan Westmoreland; Elena V Ryzhova; Julio Martín-García; Samantha S Soldan; Andrew Lackner; Francisco González-Scarano
Journal:  J Neurovirol       Date:  2006-04       Impact factor: 2.643

4.  Management of drug resistance in the population: influenza as a case study.

Authors:  Seyed M Moghadas
Journal:  Proc Biol Sci       Date:  2008-05-22       Impact factor: 5.349

5.  Increased misincorporation fidelity observed for nucleoside analog resistance mutations M184V and E89G in human immunodeficiency virus type 1 reverse transcriptase does not correlate with the overall error rate measured in vitro.

Authors:  W C Drosopoulos; V R Prasad
Journal:  J Virol       Date:  1998-05       Impact factor: 5.103

6.  Virus dynamics and drug therapy.

Authors:  S Bonhoeffer; R M May; G M Shaw; M A Nowak
Journal:  Proc Natl Acad Sci U S A       Date:  1997-06-24       Impact factor: 11.205

Review 7.  Role of glycosphingolipids in dendritic cell-mediated HIV-1 trans-infection.

Authors:  Wendy Blay Puryear; Suryaram Gummuluru
Journal:  Adv Exp Med Biol       Date:  2013       Impact factor: 2.622

8.  Distribution of HIV-1 infection in different T lymphocyte subsets: antiretroviral therapy-naïve vs. experienced patients.

Authors:  Raul Perez; Sonia Gibson; Pablo Lopez; Ellen Koenig; Marisol De Castro; Yasuhiro Yamamura
Journal:  AIDS Res Hum Retroviruses       Date:  2010-11-07       Impact factor: 2.205

Review 9.  Guidelines for antiretroviral therapy for HIV infection. Canadian HIV Trials Network Antiretroviral Working Group.

Authors:  A R Rachlis; D P Zarowny
Journal:  CMAJ       Date:  1998-02-24       Impact factor: 8.262

10.  Excision of HIV-1 DNA by gene editing: a proof-of-concept in vivo study.

Authors:  R Kaminski; R Bella; C Yin; J Otte; P Ferrante; H E Gendelman; H Li; R Booze; J Gordon; W Hu; K Khalili
Journal:  Gene Ther       Date:  2016-05-19       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.